Jupiter Neurosciences (Nasdaq: JUNS) Investor Webinar - January 6, 2026

In our live investor event, Jupiter Neurosciences CEO Christer Rosén and President Allison Silva outlined the company’s dual-engine growth strategy—targeting near-term nutraceutical revenue through its Nugevia™ product line and long-term pharmaceutical innovation via its proprietary JOTROL™ platform.

Jupiter is uniquely positioned as a biotech with a validated therapeutic platform and an active revenue engine—targeting CNS diseases and the booming wellness market. With multiple catalysts expected in 2025–2026, including clinical data and consumer growth, this is a story to watch closely.

🔗 Jupiter Neurosciences is a client of RedChip. To learn more about JUNS and to read our full disclosure, visit: JUNSinfo.com.

#LongevityInvesting #BiotechStocks #SmallCapStocks #ParkinsonsResearch #AgingScience #Healthspan #Neurodegeneration #InvestorWebinar #ClinicalTrials #Nutraceuticals #WellnessMarket #AntiInflammatory #MitochondrialHealth #JOTROL #JUNS #RedChip #LifeSciences #LongevityScience #Resveratrol

Видео Jupiter Neurosciences (Nasdaq: JUNS) Investor Webinar - January 6, 2026 канала RedChip Companies